rttnews.comOCT 121 min read$FRNM

Freenome To Present Improved Precancerous Lesion Detection Data For CRC Blood Test

Freenome (FRNM) will present data at the ACG 2026 Annual Meeting showing improved sensitivity in its updated SimpleScreen CRC blood test for detecting precancerous lesions and colorectal cancer. The test's sensitivity for advanced precancerous lesions increased to 18.2% from 13.7%, and for those with high-grade dysplasia, it rose to 41.9% from 30.5%. Shares rose 3.42% in overnight trading on Sunday.

Original reporting

rttnews.com

Published Oct 12, 2026, 4:52 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 12, 2026, 4:56 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$FRNM

Bullish

high confidence

Mentioned

$FRNM

Relevance

8/10

AlphAI data visualization · based on rttnews.com

Decision brief

The 30-second read

$FRNMBullishHigh

Why it matters

The disclosed sensitivity improvements could accelerate adoption and drive near‑term stock momentum.

Market read

First‑time release of improved clinical data is a catalyst for FRNM, likely prompting short‑term buying pressure.

What to watch

Reimbursement landscape and competition from other blood‑based CRC tests

Relevance 8/10Novelty 8/10Timing: overnight Sunday, pre‑market Monday

Background

Freenome is a Nasdaq‑listed biotech focused on early cancer detection using blood‑based assays. The SimpleScreen CRC test is partnered with Abbott Cancer Diagnostics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$FRNMBullishHigh confidence

Context

Freenome presented new clinical validation data showing higher sensitivity for advanced precancerous lesions in its SimpleScreen CRC test.

Expected impact

likely upward pressure as market prices in the stronger sensitivity figures

Evidence & confidence

The data are first‑time disclosed, show material improvement over prior results, and were released ahead of a major conference, prompting immediate market reaction.

Market effects

Sector

enhances outlook for liquid biopsy and early‑cancer detection sector

Regional

U.S. biotech market may see modest lift

Global

limited to cancer‑screening niche

Counterpoint

What could challenge this read

Investors may question commercial viability despite better sensitivity

Key entities

Company
Freenome, Inc.
Developer of the SimpleScreen colorectal cancer blood test
Partner
Abbott Cancer Diagnostics
Commercial partner for the CRC test launch

Read at source ← All news

OCT 13

$FRNMMedAI 8/10

Freenome Sinks 11% Despite “Clinically Meaningful” Gains for Next-Gen Colon Cancer Blood Test

Freenome's shares dropped 11% despite reporting improved precancer detection rates for its SimpleScreen CRC blood test. The updated test showed 18.2% sensitivity for advanced precancerous lesions, up from 13.7%, but cancer detection remained at 80.4%. Analysts project revenue to double from $102M in 2026 to $208M in 2028, driven by Abbott's sales of the first-generation test.

finance.yahoo.com2 min

OCT 12

$FRNMMed

Freenome Highlights Improved SimpleScreen CRC Performance Data At ACG 2026; Stock Up

Freenome (FRNM) announced improved performance data for its updated SimpleScreen CRC blood test at the ACG 2026 meeting. The test showed 18.2% sensitivity for advanced precancerous lesions (APLs) and 80.4% for colorectal cancer (CRC). CEO Aaron Elliott highlighted the potential clinical significance. The stock rose 3.42% in overnight trading to $16.32.

rttnews.com3 min

OCT 11

$FRNMMedAI 9/10

Freenome, Inc. (FRNM) Updates CRC Blood Test: 80.4% Sensitivity at 90% Specificity

Freenome updated its SimpleScreen CRC blood test, reporting 80.4% sensitivity at 90% specificity and improved advanced precancerous lesion detection. The company aims for regulatory clearance and increased adoption through Abbott sales.

tradingview.com1 min

OCT 11

$FRNMMedAI 8/10

An updated blood test detected 18.2% of advanced precancerous growths, versus 13.7% in the earlier study.

Freenome (FRNM) announced improved performance in its updated SimpleScreen CRC blood test, detecting 18.2% of advanced precancerous lesions compared to 13.7% in the earlier study. The test was FDA-approved in July 2026 and commercially launched in September. Results will be presented at the ACG 2026 Annual Meeting.

stocktitan.net2 min

SEP 30

$ABTMed

Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome

Abbott (ABT) launched SimpleScreen CRC, a blood test for colorectal cancer screening, developed by Freenome and FDA-approved. It will be sold alongside Cologuard Plus, acquired via Exact Sciences. The test has 81.1% sensitivity for cancer. Medicare covers it for eligible patients. The ACS recommends blood tests only for those who decline preferred methods.

massdevice.com2 min

SEP 21

$VOGXMedAI 8/10

Biotech Stocks At 52-Week Highs - HSCS +7%, FRNM +5%, VOGX, HTFL, HALO

Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.

rttnews.com4 min